Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6916470

Title:Methods for use of mpl ligands with primitive human stem cells
Inventors:Murray, Lesley J.; San Jose, CA, USA
Young, Judy C.; Mountain View, CA, USA
Summary:Described herein are methods of use for myeloproliferative leukaemia (mpl) receptor ligands, such as thrombopoietin. The invention relates to the action of such mpl ligands on a primitive subpopulation of human stem cells having the characteristics of self-renewal and the ability to give rise to all hematopoietic cell lineages. The thrombopoietin mpl ligand has been found to support both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (namely, CD34+Lin-, CD34+Thy-1+Lin-, and CD34+Lin-Rh123lo), while also stimulating quiescent human stem cells to begin cycling. Further disclosed are methods by which mpl ligands are useful for the restoration of hematopoietic capabilities. Therapeutic applications in gene therapy are provided.
Abstract:Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin, CD34+Thy-1+Lin, and CD34+LinRh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6916470
Application Number:US2001000052879
Date Filed:22/10/2001
Date Published:12/07/2005
Assignee:Novartis AG, Basel, Switzerland


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021